Ge Long Hui·2025-10-14 06:13Core Viewpoint - Goldman Sachs upgraded the rating of Tiger Med's A-shares from "Neutral" to "Buy," raising the target price from 62.1 yuan to 77.1 yuan, and initiated coverage on Tiger Med's H-shares with a "Buy" rating and a target price of 62.1 HKD [1] Group 1: Company Analysis - The stock has underperformed compared to the domestic healthcare sector, indicating an attractive entry point at present [1] - The expectation of accelerated growth in new orders in Q4 of this year, along with improved earnings visibility from 2026 to 2028, is anticipated to drive the stock price [1] Group 2: Industry Outlook - A turning point is expected in the industry, with a recovery anticipated between late 2025 and 2026, primarily benefiting from a strong rebound in fundraising and increased upfront payments from authorized collaborations [1] - Prices are expected to stabilize by the end of 2024 and continue to rise thereafter [1]